Humanized Anti-CD70 Binding Agents and Uses Thereof
AssigneeSeattle Genetics, Inc.
InventorsCHARLOTTE MCDONAGH, PAUL CARTER
Life of this patent
Estimating the term…
Abstract
Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
Claims32
1-38. (canceled)
An isolated polynucleotide encoding a humanized heavy chain variable region comprising the three CDRs from SEQ ID NO:2 and a variable region framework sequence of human germline VH1-2 or VH1-18 and exon JH-6, provided that any of positions H46, H67, H68, H69, H70, H71, H80, H81, H82, H82A and H91 (Kabat numbering) can be occupied by the amino acid occupying the corresponding position from SEQ ID NO:2.
An isolated polynucleotide, comprising the nucleotide sequence set forth in SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, or nucleotides 58-411 of SEQ ID NO:3.
An isolated polynucleotide encoding a humanized light chain variable region comprising the three CDRs from SEQ ID NO:22 and a variable region framework sequence of human germline Vκ exon B3 and Jκ exon Jκ-1, provided that any of positions L25 and L33 can be occupied by the amino acid occupying the corresponding position from SEQ ID NO:22.
An isolated polynucleotide, comprising the nucleotide sequence set forth in SEQ ID NO:23.
Dependencies are inferred from the claim text.